Psychiatry and neurological diseases

Pharmacological treatments are a cornerstone in managing psychiatric and neurological disorders. However, most treatment recommendations are based on findings from clinical trials, which often have limitations. These studies typically include small, carefully selected populations (e.g., excluding individuals with comorbidities such as substance use disorders or suicidal behavior) and are limited to short follow-up periods.

At CPE, we use pharmacoepidemiological methods to address these gaps. By studying large populations of "real-world" patients, often with extended follow-up times, we provide representative and generalizable insights into treatment outcomes.

Our research in psychiatry includes completed and ongoing projects on treatment-resistant depression, medication adherence in schizophrenia and bipolar disorder, as well as the use of hypnotics and antidepressants. In neurology, we focus on treatments for migraine and multiple sclerosis. A key area of interest is also the safety of psychiatric and neurological medications during pregnancy.

The research area is led by: